Company: APXIF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026189
Chunk: 1168

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 6
Chunk 1168
---
 of public shares who elect to have their shares redeemed in connection
with the consummation of our initial business combination.

On December 20, 2023, January 24, 2024, February 12, 2024, March 12,
2024, April 8, 2024 and May 28, 2024, we deposited $125,000 each month into the Trust Account in order to effect six one-month extensions
of the termination date to June 9, 2024. On September 27, 2024, the Company deposited $375,000 (plus accrued interest) into
the Trust Account representing $125,000 for each of the months of June 2024, July 2024 and August 2024, in order to extend the termination
date to September 9, 2024. On November 8, 2024, the Company deposited a lumpsum of $375,000 for back payments to the Trust
representing $125,000 for each of the months of September 2024, October 2024, and November 2024 to extend the termination date to
December 9, 2024.

Class B Conversion 

On October 2, 2023, in accordance with the provisions of our Articles,
Templar Sponsor exercised its rights to convert an aggregate of 4,312,500 Class B ordinary shares into an equal number of Class A Ordinary
Shares, on a one-for-one basis (the “Class B Conversion”). As a result of the Class B Conversion, no Class B ordinary shares
remain outstanding.

Promissory Notes

On August 26, 2024, the Company issued the
unsecured First Bioceres Note in the principal amount of $446,000 to Bioceres, an indirect shareholder of OmnigenicsAI. The First Bioceres
Note bears interest at 20% per annum. The Company shall repay all interested accrued and the principal balance on the date on which the
Company consummates its initial business combination. The First Bioceres Note is subject to customary events of default, the occurrence
of certain of which automatically triggers the unpaid principal balance of the First Bioceres Note as well as all accrued interest and
all other sums payable with regard to the First Bioceres Note becoming immediately due and payable.

On November 7, 2024, the Company issued the unsecured
Second Bioceres Note in the principal amount of $